Evidence map›Paper›PMID 33640794›Full record

ArticleEBioMedicine2021

A clinical trial of non-invasive imaging with an anti-HIV antibody labelled with copper-64 in people living with HIV and uninfected controls.

James H McMahon, Jennifer M Zerbato, Jillian S Y Lau, Jaclyn L Lange, Michael Roche, Carolin Tumpach, Ashanti Dantanarayana, Ajantha Rhodes, Judy Chang, Thomas A Rasmussen and 21 more

Open access · goldAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in EBioMedicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Advances and challenges in immunoPET methodology.Frontiers in nuclear medicine · 2024
    Review
  7. Article
  8. Review
  9. Review
  10. Isotopic Radiolabeling of the Antiretroviral Drug [Pharmaceuticals (Basel, Switzerland) · 2022
    Article
  11. Article
  12. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

31 authors at 8 institutions in 2 countries.

James H McMahonDepartment of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia; Department of Infectious Diseases, Monash Health, Melbourne, Australia.
Jennifer M ZerbatoThe Peter Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital, Melbourne, Australia.
Jillian S Y LauDepartment of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia.
Jaclyn L LangeAustralian Centre for Blood Diseases, Monash University, Melbourne, Australia.
Michael RocheThe Peter Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital, Melbourne, Australia.
Carolin TumpachThe Peter Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital, Melbourne, Australia.
Ashanti DantanarayanaThe Peter Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital, Melbourne, Australia.
Ajantha RhodesThe Peter Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital, Melbourne, Australia.
Judy ChangThe Peter Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital, Melbourne, Australia.
Thomas A RasmussenThe Peter Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital, Melbourne, Australia.
Charlene A MackenzieThe Peter Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital, Melbourne, Australia.
Karen AltAustralian Centre for Blood Diseases, Monash University, Melbourne, Australia.
Michelle HagenauerDepartment of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia.
Janine RoneyDepartment of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia.
Jessica O'BryanDepartment of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia; Department of Infectious Diseases, Monash Health, Melbourne, Australia.
Alexandra CareyMonash Biomedical Imaging, Monash University, Melbourne, Australia.
Richard McIntyreMonash Biomedical Imaging, Monash University, Melbourne, Australia.
Paul BeechMonash Biomedical Imaging, Monash University, Melbourne, Australia.
Graeme J O'KeefeDepartment of Molecular Imaging and Therapy, Austin Health, and University of Melbourne, Melbourne, Australia; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, School of Cancer Medicine, La Trobe University, Melbourne, Australia.
Christian W WichmannDepartment of Molecular Imaging and Therapy, Austin Health, and University of Melbourne, Melbourne, Australia; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, School of Cancer Medicine, La Trobe University, Melbourne, Australia.
Fiona E ScottDepartment of Molecular Imaging and Therapy, Austin Health, and University of Melbourne, Melbourne, Australia; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, School of Cancer Medicine, La Trobe University, Melbourne, Australia.
Nancy GuoTumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, School of Cancer Medicine, La Trobe University, Melbourne, Australia.
Sze-Ting LeeDepartment of Molecular Imaging and Therapy, Austin Health, and University of Melbourne, Melbourne, Australia; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, School of Cancer Medicine, La Trobe University, Melbourne, Australia.
Zhanqi LiuDepartment of Molecular Imaging and Therapy, Austin Health, and University of Melbourne, Melbourne, Australia; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, School of Cancer Medicine, La Trobe University, Melbourne, Australia.
Marina CaskeyLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, United States.
Michel C NussenzweigLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, United States; Howard Hughes Medical Institute, The Rockefeller University, New York, NY, United States.
Paul S DonnellySchool of Chemistry, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, Australia.
Gary EganMonash Biomedical Imaging, Monash University, Melbourne, Australia.
Christoph E HagemeyerAustralian Centre for Blood Diseases, Monash University, Melbourne, Australia.
Andrew M ScottDepartment of Molecular Imaging and Therapy, Austin Health, and University of Melbourne, Melbourne, Australia; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, School of Cancer Medicine, La Trobe University, Melbourne, Australia.
Sharon R LewinDepartment of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia; The Peter Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital, Melbourne, Australia.
The Royal Melbourne Hospital · AUMonash University · AUThe University of Melbourne · AUAustralian Centre for HIV and Hepatitis Virology Research · AUMonash Alfred Psychiatry Research centre · AUHoward Hughes Medical Institute · USLa Trobe University · AURockefeller University · US

Funding

Viral reservoirs and sanctuaries in HAART - treated patients: role and mechanismsU19AI096109 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SCHACKER, TIMOTHY W · 2011 to 2015
$29.5M
NIAID NIH HHS U19 AI096109
6 · The paper itself

Abstract

backgroundA research priority in finding a cure for HIV is to establish methods to accurately locate and quantify where and how HIV persists in people living with HIV (PLWH) receiving suppressive antiretroviral therapy (ART). Infusing copper-64 (

methodsUnmodified 3BNC117 was compared with 3BNC117 bound to the chelator MeCOSar and

findingsComparison of unmodified and modified 3BNC117 in vitro demonstrated no difference in HIV binding or neutralisation. 17 individuals were enrolled of which 12 were dosed including Group 1 (n=4, 2 high protein, 2 trace dose), Group 2 (n=6, 2 high protein, 4 trace) and Group 3 (n=2, trace only). HIV+ participants had a mean CD4 of 574 cells/microL and mean age 43 years. There were no drug related adverse effects and no differences in tissue uptake in regions of interest (e.g lymph node gut, pharynx) between the 3 groups. In the high protein dosing group, serum concentrations of 3BNC117 and gamma counts were highly correlated demonstrating that

interpretationIn PLWH on or off ART, the intervention of infusing

fundingFunded by the Alfred Foundation, The Australian Centre for HIV and Hepatitis Virology Research with additional support from the Division of AIDS, National Institute of Allergy and Infectious Disease, US National Institutes of Health (USAI126611). JHM and SRL are supported by the Australian National Health and Medical Research Council.

Indexed as

AdultAntibodies, MonoclonalAnti-Retroviral AgentsCase-Control StudiesCD4-Positive T-LymphocytesCopper RadioisotopesFemaleHalf-LifeHIV-1HIV AntibodiesHIV Envelope Protein gp120HIV InfectionsHumansIsotope LabelingMaleMiddle AgedAntibodies, MonoclonalAnti-Retroviral AgentsCopper-64Copper RadioisotopesHIV AntibodiesHIV Envelope Protein gp120RadiopharmaceuticalsBroadly neutralising antibodiesClinical trialHIVImagingPET scan

Identifiers

PMID33640794
PMCPMC7921458
OpenAlexW3131317734

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.